AstraZeneca’s supplemental new drug application (sNDA) for lead lung cancer drug Tagrisso (Osimertinib) in combination with chemotherapy has been accepted and granted priority review in the US.
A kidney disease drug with a ‘durable and clinically meaningful impact on kidney function’ has been granted priority review by the US Food and Drug Administration (FDA).